Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced MyocarditisAlexi Vasbinder, Salim S. Hayek, Pennelope Blakely et al.|JACC CardioOncology|2022Cited by 78
Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19Alexi Vasbinder, Salim S. Hayek, Élizabeth Anderson et al.|Diabetes Care|2022Cited by 74
Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19Alexi Vasbinder, Chelsea Meloche, Tariq U. Azam et al.|Circulation Cardiovascular Quality and Outcomes|2022Cited by 34
Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19Michael Pan, Alexi Vasbinder, Élizabeth Anderson et al.|Journal of the American Heart Association|2021Cited by 29
Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19Shengyuan Luo, Yiyuan Huang, Alexi Vasbinder et al.|Journal of the American Heart Association|2022Cited by 16